Immunochemotherapy for advanced bladder cancer using FT-207, adriamycin and OK-432.
A combination therapy consisting of daily intrarectal administration of 1,500 mg of FT-207 suppository, daily or every three day bladder instillation of 40 mg adriamycin for a total of 20 applications, and once per week intramuscular administration of 5 KE OK-432 was described. The therapy was performed in 30 cases of advanced bladder cancer. The effectiveness evaluated by Karnofsky's criteria was as follows: 8 cases of 0-0, 2 of 0-A, 1 of 0-B, 2 of 0-C, 7 of 1-A and 10 of 1-B, showing an effective rate of 57%. Local pain was observed in 20 cases (67%), pancytopenia in 1 (3%), hepatitis in 4 (13%), stomatitis in 5 (17%) and anorexia in 6 (20%). From this clinical trial, it is presumed that combination therapy administering FT-207 intrarectally, adriamycin intravesically and OK-432 intramuscularly might be used for the treatment of advanced bladder cancer provided sufficient care is taken of general side effects.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000368:Aged; D004317:Doxorubicin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006801:Humans; D007273:Injections, Intramuscular; D013291:Streptococcus / Q000276:immunology; D013488:Suppositories; D005641:Tegafur / Q000008:administration & dosage*; D014463:Ultrasonography; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D013488:Suppositories; D005641:Tegafur; D004317:Doxorubicin; D005472:Fluorouracil